decisionhealth Newsletters, Answer Books - 2011 Issue 7 (July)
Appendix E - National Coverage Determinations Manual / Autologous Cellular Immunotherapy Treatment 110.22
Subscribe or sign in to view the full article.
Article Overview
This article covers the Medicare National Coverage Determinations Manual entry for autologous cellular immunotherapy treatment, including the FDA-approved therapy discussed, the clinical context for metastatic prostate cancer, and the general coverage status for on-label and off-label use. It is relevant to coders, billers, and reimbursement staff who need to understand the policy framework, effective dates, and how CMS addresses this service under Medicare coverage guidance.
Why This Topic Matters
Coverage determinations can affect whether a service is reimbursable under Medicare and whether local contractors retain discretion for certain uses. Understanding the policy scope helps prevent miscoding, coverage denials, and misinterpretation of the applicable national guidance.
Article Sections
-
General
Provides clinical background on the therapy and the disease context discussed in the coverage policy. It also summarizes the treatment approach at a high level and identifies the regulatory setting.
-
Indications and Limitations of Coverage
Introduces the Medicare coverage framework for this therapy and separates the policy into covered, non-covered, and other coverage considerations.
-
Nationally Covered Indications
Describes the general scope of the nationally covered use under the policy and notes the effective date.
-
Nationally Non-Covered Indications
States whether any nationally non-covered indications are identified in the policy.
-
Other
Addresses additional coverage handling for uses outside the on-label indication and identifies the role of local Medicare contractors.
What You Will Learn
- The clinical and policy context for autologous cellular immunotherapy in Medicare coverage guidance.
- How the article distinguishes covered use, non-covered use, and other coverage handling.
- Which organizations and regulatory bodies are referenced in the coverage discussion.
- The effective-date framework associated with the National Coverage Determination.
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Compliance teams
- Practice administrators
- Healthcare reimbursement analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com